Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1RAs for Smoking Cessation in Type 2 Diabetes
NCT06924697Enrolling by invitation
- Sponsor
- Shanghai East Hospital
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of semaglutide in nicotine dependence (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: Fagerstrom Test of Nicotine Dependence at 24 weeks. Started Jun 2025; status: enrolling by invitation.
02
Drugs
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT06924697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924697.